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Edited by Veli-Pekka LehtoAbstract Treatment of diﬀerent cancer cell lines with desipra-
mine induced a time- and dose-dependent downregulation of acid
ceramidase. Desipramine’s eﬀect on acid ceramidase appeared
speciﬁc for amphiphilic agents (desipramine, chlorpromazine,
and chloroquine) but not other lysomotropic agents such as
ammonium chloride and baﬁlomycin A1, and was not transcrip-
tionally regulated. The cathepsin B/L inhibitor, CA074ME, but
not the cathepsin D inhibitor, pepstatin A, blocked desipramine’s
eﬀect on acid ceramidase. Desipramine led to a more pronounced
downregulation of sphingosine compared to ceramide suggesting
acid ceramidase inhibition is important to desipramine’s mecha-
nism of action. This study reveals a new mechanism of action for
desipramine.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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drugs1. Introduction
Studies have shown that the tricyclic anti-depressant desi-
pramine induces intracellular proteolytic degradation of ma-
ture acid sphingomyelinase but not other lysosomal enzymes,
and accordingly it has been widely used in the literature as a
speciﬁc acid sphingomyelinase inhibitor [1,2]. Desipramine ef-
fect on acid sphingomyelinase has been also observed to be in-
duced by other cationic amphiphilic drugs, but not by neutral
or anionic ones [3]. Acid sphingomyelinase is normally local-
ized in the lysosome and hydrolyses sphingomyelin generating
ceramide, a major tumor suppressor lipid [4]. Ceramide is an
intracellular mediator for a wide variety of extracellular agents
known to induce apoptosis including ionizing radiation, che-
motherapy, Fas ligand and tumor necrosis factor a [4]. In most
cases, desipramine was able to block cell killing induced by
such cytotoxic agents, which was attributed to blockade of cer-
amide generation through inhibition of acid sphingomyelinase
[4–8].*Corresponding author. Fax: +1 843 792 4882.
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doi:10.1016/j.febslet.2006.07.071In 1995, another ceramide metabolizing enzyme, human acid
ceramidase was puriﬁed and characterized [9]. Similar to acid
sphingomyelinase, acid ceramidase is found predominantly in
the lysosomal compartment. However, unlike acid sphingomy-
elinase which generates ceramide, acid ceramidase deacylates
ceramide to generate sphingosine and a fatty acid [4,10].
Sphingosine is an important cell signaling sphingolipid
molecule that is also implicated in apoptosis [4]. Moreover,
sphingosine can be further metabolized to sphingosine-1-
phosphate, another bioactive sphingolipid that often exerts
anti-apoptotic functions [4].
In this report, we show that the widely used inhibitor of acid
sphingomyelinase desipramine is also an inhibitor of sphingo-
sine generation acid ceramidase. We believe that this informa-
tion is highly valuable in re-evaluating some of the conclusions
that were based on the assumption that desipramine eﬀects are
solely due to inhibition of acid sphingomyelinase.2. Materials and methods
2.1. Cell lines
The human prostate cancer cell line DU145, bladder cancer cell line
5637, and Hela cervical cancer cell line were all purchased from ATCC
(Manassas, VA, USA), and cultured in RPMI 1640 (Mediatech Inc.,
Herndon, VA, USA) supplemented with 10% heat-inactivated bovine
growth serum (Hyclone, Logan, UT, USA). The head and neck cancer
cell line SCC-14A, was acquired from Dr. Thomas E. Carey (Univer-
sity of Michigan, Ann Arbor, MI) and maintained in DMEM 1·
MOD medium with L-glutamine and 4.5 g/L glucose (Media-tech,
Herndon, VA), supplemented with 10% heat-inactivated bovine
growth serum. Cells were maintained in 5% CO2 at 37 C.2.2. Reagents
Desipramine, pepstatin A, and leupeptin were purchased from
Sigma (St. Louis, MO, USA), CA074Me was purchased from
Calbiochem (San Diego, CA, USA), and baﬁlomycin A1 was obtained
from BIOMOL. LysoTracker Red was obtained from Molecular
Probes (Eugene, OR, USA). Antibodies used for immunoblotting
were anti-acid ceramidase (Pharmingen, San Diego, CA, USA), rabbit
anti-cathepsin L (Calbiochem), mouse anti-cathepsin B (Oncogene),
mouse anti-LAMP-1 (BD Pharmingen), goat anti-mouse IgG-HRP
conjugate (Sigma), and goat anti-rabbit IgG-HRP conjugate (Santa
Cruz).2.3. Lysosomal stability assay
Lysosomal stability was measured using the ﬂuorescent dye Lyso-
Tracker Red (LTR). Cells were seeded overnight in 60 mm plates.
The next day, medium was removed and replaced with medium con-
taining 200 nM LTR. Cells were loaded with LTR for 30 min atblished by Elsevier B.V. All rights reserved.
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PBS, followed by addition of fresh medium containing the treatment
(10 lm desipramine, 10 mM NH4Cl or 100 lM baﬁlomycin A1) and
incubated for 3 h at 37 C. After treatment, cells were lifted with tryp-
sin, washed once in PBS, and resuspended in 0.5 ml growth medium.
LTR ﬂuorescence was measured by FACS analysis (564–606 nm).
A decrease in ﬂuorescence intensity corresponds to an increase in
lysosomal pH, and a minimum of 10000 events were scored for each
sample.
2.4. Ceramide measurement
2.1 · 106 cells were seeded in 100 mm plates overnight. The next day,
media were removed and replaced with media containing vehicle con-
trol or desipramine (10 lM) for the indicated time. Following treat-
ment, cells were harvested by gentle scraping and immediate
centrifugation at 4 C for 5 min at 400 · g. Cell pellets were resus-
pended in ice cold PBS and stored at 80 C. For sphingolipid analy-
sis, lipid extracts were examined by mass spectrometry as previously
described [11].
2.5. Immunoblot analysis
Cells were seeded in 60 mm plates as described above and treated
accordingly. Cells were lifted by gently scraping the plates, washed
once with ice cold PBS and lysed in lysis buﬀer (PBS, 1% Triton X-
100, 10% glycerol) containing protease inhibitors pepstatin A (0.5 lg/
ml), leupeptin (0.5 lg/ml), aprotinin (5 lg/ml), and PMSF (100 lg/
ml) for 10 min on ice. Insoluble material was removed by centrifuga-
tion at 14000 rpm for 15 min at 4 C. The supernatants were then sup-
plemented with SDS to a ﬁnal concentration of 2% and stored at
80 C. Protein concentrations were determined using the DC Protein
Assay (BioRad Laboratories, Hercules, CA, USA) according to the
manufacturer’s instructions. Fifty micrograms of protein per sample
was separated on NuPAGE 4–12% bis–tris gels (Invitrogen, Carlsbad,
CA, USA) and transferred to nitrocellulose membranes (BioRad). Fol-
lowing transfer, membranes were blocked for 1 h at room temperature
in tris-buﬀered saline (TBS) containing 0.1% Tween-20 and 5% non-fat
dry milk and incubated overnight at 4 C with primary antibody at a
dilution of 1:2000 (actin), 1:250 (acid ceramidase), 1:300 (LAMP–1),
1: 400 (cathepsin B), 1:2000 (cathepsin L). Overnight incubations were
performed in 5% milk in TBS-Tween. Following overnight incubation,
membranes were washed three times for 10 min each in TBS-Tween
and incubated for 1 h at room temperature with secondary antibody
in 5% milk TBS-Tween at a dilution 1:5000 (goat anti-mouse IgG)
or 1:50000 (goat anti-rabbit). Membranes were then washed three
times more and incubated for 5 min at room temperature with Super
Signal HRP substrate (Pierce Biotechnology Inc., Rockford, IL, USA).
2.6. Reverse transcriptase PCR
DU145 cells were seeded in six-well plates as described above. The
next day media were gently removed and replaced with media contain-
ing 2% BGS and desipramine (10 lM) or ethanol control. Cells were
collected at the indicated time points, and total RNA was extracted
using RNAqueous-4PCR kit (Ambion Inc., Austin, TX), including
the DNase I treatment step to remove DNA contamination. The level
of acid ceramidase mRNA was assayed by a two-step RT-PCR proto-
col (Ambion), and Rig/S15 was used as an internal control. The se-
quence of the primer for ampliﬁcation of acid ceramidase was as
follows: F – tgtggatagggttcctcactaga, R – ttgtgtatacggtcagcttgttg
375 bp. All reactions were performed in a programmable thermal cycler
(reverse transcription at 55 C for 1 h; PCR at 95 C, 3 min; 95 C, 30 s;
52 C, 1 min and extension at 72 C for 1 min; ﬁnal extension at 72 C,
10 min). The PCR product was separated on a 2% agarose gel.3. Results
3.1. Desipramine induces the downregulation of acid ceramidase
We ﬁrst determined the eﬀects of 10 lM desipramine on acid
ceramidase in DU145 cancer cells. As seen in the western blot
(Fig. 1A), desipramine-induced downregulation of acid ceram-
idase within 15 min and the enzyme was below detection level
by 1 h. The levels of other lysosomal proteins such as LAMP-1, cathepsin B and cathepsin L did not decrease following
treatment with desipramine or increased (Fig. 1B). Acid cer-
amidase downregulation was also observed to be dose depen-
dent (Fig. 1C). Furthermore, the action of desipramine was
not cell line dependent since we also observed acid ceramidase
downregulation in three additional cell lines, SCC-14A, 5637
and HeLa cells (Fig. 1D). Similarly, desipramine-induced acid
ceramidase downregulation has been also described recently in
the mouse ﬁbroblast cell line L929 [12]. Finally, we show that
similar to desipramine, other cationic amphiphilic drugs that
previously have been shown in the literature to downregulate
acid sphingomyelinase (chloroquine and chlorpromazine) [13]
were able to downregulate acid ceramidase (Fig. 1E). These re-
sults demonstrate that desipramine (and related amphiphilic
molecules) induces a time- and dose-dependent downregula-
tion of acid ceramidase, at the same concentration that is used
in the literature to inhibit acid sphingomyelinase.3.2. Cysteine proteases are involved in acid ceramidase
degradation
Next, we wanted to determine the mechanism of downregu-
lation of acid ceramidase. Desipramine treatment did not
change acid ceramidase mRNA steady-state levels as deter-
mined by RT-PCR, demonstrating that downregulation was
not due to decreased transcription or changes in message sta-
bility (Fig. 2A).
Next, the role of lysosomal pH in regulating the levels of acid
ceramidasewas investigated since desipramine is known to aﬀect
lysosomal pH. Treatment of cells with desipramine andwith two
other lysomotropic drugsNH4Cl and baﬁlomycinA1 resulted in
loss of lysosomal pH as judged by loss of lysotracker red inten-
sity (Fig. 2B). However, unlike desipramine, NH4Cl and baﬁlo-
mycin A1 did not downregulate acid ceramidase (Fig. 2B),
suggesting that neutralizing lysosomal pH was not suﬃcient to
produce desipramine-induced acid ceramidase downregulation.
Since acid ceramidase resides in the protease-rich lysosomes,
lysosomal proteases seemed to be likely candidates for mediat-
ing the downregulation of acid ceramidase. To investigate this
we tested several protease inhibitors including the broad spec-
trum cysteine protease inhibitor leupeptin (25 lM), the cathep-
sin B/L speciﬁc inhibitor CA074ME (10 lM) [14,15], and the
cathepsin D inhibitor pepstatin A (1 lg/ml). Although pepsta-
tin A had no eﬀect on acid ceramidase downregulation, leupep-
tin and CA074ME almost completely reversed acid ceramidase
downregulation in desipramine treated cells (Fig. 2C). These
data strongly suggest that downregulation of acid ceramidase
by desipramine is mediated through a cathepsin B/L dependent
pathway.3.3. Sphingolipid modulation following treatment with
desipramine
Desipramine has been widely used as an agent to inhibit cer-
amide generation through acid sphingomyelinase. Since we
have now demonstrated above that desipramine degrades acid
ceramidase, which deacylates ceramide generating sphingosine,
we quantiﬁed by mass spectrometry the amount of sphingomy-
elin, ceramide and sphingosine in DU145 cells following treat-
ment with desipramine. We observed that 10 lM desipramine
treatment resulted in an accumulation of sphingomyelin
(Fig. 3A), consistent with its inhibitory eﬀect on acid sphingo-
myelinase. Total ceramide levels did not decrease and were in-
Fig. 1. Downregulation of acid ceramidase by desipramine and other cationic amphiphilic drugs. DU 145 cells were plated overnight in 10% DMEM
and treated with 10 lM desipramine for the indicated time points (A) or for 6 h with the indicated desipramine concentrations (C). Following
treatment, cells were collected, lysed, and proteins were analyzed by Western blotting as described in Section 2. B represents densitometry analysis of
the blot in A normalized to actin. In D, SCC-14A, 5637 and HeLa cells were treated with 10 lM desipramine for 6 h then subjected to Western
blotting. E is a Western blot of Du145 treated for 6 h with 5 lM desipramine, chloroquine or chlorpromazine. All Western blots have been performed
at least twice with the same results.
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was surprising in view of its projected mechanism of action
and use as an inhibitor of acid sphingomyelinase. However,
since acid ceramidase is a key enzyme in ceramide metabolism
and we have demonstrated its degradation by desipramine
(Figs. 1 and 2), we would expect that ceramide might increase
with a concomitant decrease in sphingosine levels following
drug treatment which was what we observed (Fig. 3C). These
results support the dual eﬀects of desipramine on both acid
sphingomyelinase and acid ceramidase.4. Discussion
In this report, we investigated the eﬀect of the amphiphilic
drug desipramine on acid ceramidase, an enzyme that metab-olizes ceramide to sphingosine. We have demonstrated that
desipramine produces a dose- and time-dependent downregu-
lation of acid ceramidase at the protein level at the relatively
low dose of 5 lM, a dose that is commonly used in the litera-
ture to inhibit acid sphingomyelinase. Other cationic amphi-
philic drugs (chlorpromazine, chloroquine) previously shown
at similar doses to inhibit acid sphingomyelinase were also ob-
served to produce the same eﬀect on acid ceramidase suggest-
ing that acid ceramidase and sphingomyelinase are both
targets for this group of compounds [13].
A number of studies have been published lately on the po-
tential use of cationic amphiphilic drugs as chemo-sensitizers,
and chemotherapeutic agents, though the mechanism of action
is still not well deﬁned [13,16,17]. From our data, it may be as
well that inhibition of acid ceramidase by these drugs plays an
important role in their chemo-sensitizing ability, especially
Fig. 2. Downregulation of acid ceramidase by desipramine is mediated through Ca074ME sensitive proteases. (A) RT-PCR of acid ceramidase in
DU 145 cells following treatment with 10 lM desipramine for the indicated time range. (B) Comparison of the eﬀect of three lysomotropic agents on
lysosomal pH. Cells were loaded with Lysotracker red for 30 min at 37 C. Lysotracker red was removed and cells were treated with 10 lm
desipramine, 10 mM NH4CL or 100 lM Baﬁlomycin A1 for 3 h followed by FACS analysis to measure Lysotracker red ﬂuorescence as described in
Section 2. A decrease in ﬂuorescence intensity corresponds to an increase in lysosomal pH. Results are expressed as mean + S.D. for at least two
diﬀerent experiments. We also measured by Western blotting the eﬀect of the same drugs on acid ceramidase levels which were also quantiﬁed by
densitometry. (C) Eﬀect of the protease inhibitors leupeptin, CA074, and pepstatin A on acid ceramidase protein levels following a 6 h treatment with
10 lM desipramine.
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Fig. 3. The eﬀect of desipramine on sphingolipid levels. Changes in sphingomyelin (A), ceramide (B), and sphingosine (C) levels in DU145 cancer
cells following treatment with 10 lM desipramine for the indicated times were determined by mass spectrometry as described in Section 2. Results are
expressed as mean + S.D. for at least two diﬀerent experiments. Statistical signiﬁcance between desipramine treatment and matched control is
determined using statistical student’s t-test. # represents p < 0.05, *represents p < 0.005, and + represents p < 0.0005.
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cancer and to play an important role in mediating resistance to
chemotherapeutics [18,19,22].
Next, we investigated the mechanism of downregulation of
acid ceramidase by desipramine. We demonstrate that down-
regulation is not due to decreased transcription. Next, the ef-
fect of desipramine on acid ceramidase could not be
reproduced by other agents that neutralize lysosomal pH
(NH4Cl, baﬁlomycin A1), suggesting that lysosomal pH dissi-
pation on its own cannot account for desipramine eﬀect on
acid ceramidase. Finally, the speciﬁc cathepsin B/L inhibitor
CA074ME [14,15] inhibited acid ceramidase degradation fol-
lowing incubation with desipramine suggesting that cathepsins
B and/or L are involved in the degradation of acid ceramidase
following incubation with desipramine.
Since desipramine downregulates two key enzymes with
opposite eﬀects on ceramide metabolism, it became important
to determine the net eﬀect of desipramine on basal levels ofceramide in cells. We found that in the prostate cancer cell line
DU145, desipramine led to accumulation of sphingomyelin
and ceramide. Importantly, desipramine induced a signiﬁcant
drop in the levels of sphingosine in DU145 cancer cells, sug-
gesting that desipramine can be used as an inhibitor of sphin-
gosine generation by acid ceramidase. Thus, desipramine
aﬀects the level of more than one functionally active sphingo-
lipid molecule, namely, sphingomyelin, sphingosine, and cera-
mide with the latter two being both implicated in apoptosis
pathways [4]. Therefore, based on the above, we recommend
that care be exercised in interpreting results with desipramine
due to the multiple eﬀects of this molecule on sphingolipid
modulating enzymes and their sphingolipid products.
Although the literature on acid ceramidase is limited com-
pared to acid sphingomyelinase, accumulating evidence sug-
gests that acid ceramidase is over-expressed in cancer and
that its over-expression mediates resistance to apoptosis induc-
tion [18,19]. Therefore, interest on developing and testing
4756 S. Elojeimy et al. / FEBS Letters 580 (2006) 4751–4756drugs that inhibit acid ceramidase is mounting with the speciﬁc
goal to develop drugs that sensitize cancer cells to chemother-
apeutic agents or radiation by inhibiting acid ceramidase
allowing ceramide levels to accumulate [20,21]. This suggests
that this class of amphiphilic drugs which downregulate acid
ceramidase might be combined with radiation or chemother-
apy to enhance ceramide upregulation and produce a more
potent therapeutic event. Since desipramine is an approved
drug for use in depression therapy such a clinical trial would
be possible to perform.
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